Sedana Medical AB (publ) publish 2016 annual report


An eventful year and a historic profit

The annual report is only available in Swedish; the information below is a summary with comments on the key figures. The interim report for the period 1 January – 31 March 2017 will although be available in English and will also include a consolidated income statement, balance sheet and cash flow analysis for the full financial year 2016.

1 January – 31 December 2016 in summary, consolidated figures

  • Net sales 32,155 TSEK (28,113 TSEK)
  • EBITDA 994 TSEK (-1,174 TSEK), corresponding to a EBITDA margin of 3.1% (-4.2%)
  • EBIT 618 TSEK (-1,387 TSEK), corresponding to a EBIT margin of 1.9% (-4.9%)
  • Net income 1,286 TSEK (-1,205 TSEK)
  • Cash flow from operations 239 TSEK
  • Net income per share* 0.15 SEK (-0.14 SEK)

*based on 8,680,000 shares outstanding

Significant events during 2016 and the start of 2017


  • Sedana Medical AB (publ) (“Sedana Medical” or “the Company”)  initiated a major clinical study in October 2016, with the aim of gaining marketing authorization approval for IsoConDa® (isoflurane), a volatile anaesthetic to be used in inhalation sedation of mechanically ventilated patients in intensive care units. The clinical study is being performed in Germany and it is expected to conclude during 2018, with registration of IsoConDa at the end of 2019.
  • In November 2016 Sedana Medical AB initiated an investigation regarding the requisites for a IPO of the Sedana Medical shares.
  • In December 2016, the development of the next AnaConDa generation, AnaConDa-S, was finalised. Market launch of the AnaConDa-S was planned for the first half of 2017.

January – April 2017  

  • On 1 February 2017 Christer Ahlberg assumed the position as the new CEO of Sedana Medical AB. Christer Ahlberg has extensive experience in leading positions, and a vast international network, in the pharmaceutical industry.
  • In March 2017 AnaConDa was approved in South Korea; the approval was the first in the Asian market.
  • At the EGM, on 5 April 2017, it was decided to perform a share split and a bonus issue, respectively, to convert the company from private to public.  

Comments from the CEO

2016 was a historical year for us at Sedana Medical since we first time ever reached a positive EBITDA of 994 TSEK. Sales developed positively reaching 32,154 TSEK, a 14% increase compared to 2015. Germany, representing 90% of our total sales, continues to grow with increasing demand from the more than 400 intensive care units, including nearly all university clinics, using the AnaConDa technology.

Strengthened by the positive development, we initiated a clinical study in Germany during the final quarter of 2016. The study will generate a registration of our pharmaceutical IsoConDa® (isoflurane) in inhalation sedation therapy in European intensive care by the end of 2019.

To secure the funding of our new business plan, including the clinical study in Europe, the initiation of a clinical study in the USA and a sales organization build-up, we initiated an investigation during autumn 2016 regarding the requisites for an IPO.

In December 2016, we finalized the development of the next generation of the AnaConDa technology – AnaConDa-S. This innovation, with its great advantages, increase the potential market by an estimated 25% and it is expected to replace the current AnaConDa completely. The commercial launch will start in the second quarter of 2017.

We ended 2016 at a high speed and we are certainly looking forward to 2017 with the clinical study and the launch of AnaConDa-S. 

For further information please contact:

Christer Ahlberg, CEO Sedana Medical AB (publ)
Mobile: +46 (0)70 – 675 33 30

Maria Engström, CFO Sedana Medical AB (publ)
Mobile: +46 (0)70 674 33 30 

View All Press Releases